Cocrystal Pharma, Inc. develops antiviral therapeutics using a proprietary structure-based drug discovery platform. News for COCP centers on CDI-988, an oral direct-acting protease inhibitor for norovirus infection, including clinical-study updates, FDA Fast Track designation and scientific presentations on its 3CL protease mechanism.
Company updates also cover financial results, financing activity, NIH-supported influenza A/B polymerase research, and broader pipeline references to respiratory viruses and coronaviruses.
Cocrystal Pharma, Inc. (Nasdaq: COCP) has commenced enrollment in a Phase 1 trial for CC-42344, an orally administered antiviral for influenza A. The company plans to initiate two additional Phase 1 trials in 2022 for COVID-19 antiviral candidates. Notably, Cocrystal reported no revenues for 2021, down from $2 million in 2020, and a net loss of $14.2 million, or $0.16 per share. However, cash reserves increased to $58.7 million, up from $33 million year-over-year, providing sufficient funds for operations through 2023.
Cocrystal Pharma, Inc. (Nasdaq: COCP) will participate in the 2022 Virtual Growth Conference hosted by Maxim Group and M-Vest from March 28-30, 2022. Interested attendees can register online. A pre-recorded presentation will be accessible for 72 hours starting March 28 at 9:00 a.m. ET. Cocrystal Pharma is focused on developing antiviral therapeutics targeting influenza, coronaviruses, hepatitis C, and noroviruses, utilizing advanced technologies and expertise.
Cocrystal Pharma has initiated dosing in a Phase 1 clinical trial for its antiviral drug CC-42344, targeting both pandemic and seasonal influenza A. Conducted in Australia, this study will assess the drug's safety and pharmacokinetics in 56 healthy adults. CC-42344 is designed to inhibit influenza viral replication and potentially act against drug-resistant strains. Results are expected later this year, marking a key step in Cocrystal's development of innovative antiviral therapies.
Cocrystal Pharma (Nasdaq: COCP) announces participation in two investment conferences. The Q1 Investor Summit on March 8-9 will feature a presentation on March 9 at 11:45 a.m. Eastern time. Additionally, the company will attend the 34th Annual Roth Conference from March 13-15 in California. Cocrystal plans to start enrollment for a Phase 1 trial of influenza A and initiate studies on two SARS-CoV-2 antivirals for COVID-19 treatments. The company emphasizes its strong financial position to support these developments.
Cocrystal Pharma (Nasdaq: COCP) announced the selection of two investigational oral antiviral candidates, CDI-988 and CDI-873, for the treatment of SARS-CoV-2, showing superior in vitro potency against the virus and its variants, including Omicron.
Both candidates are poised for first-in-human trials in 2022, leveraging Cocrystal's proprietary drug discovery platform. The company also plans to expedite the development of an inhalation candidate, CDI-45205. Positive preclinical results and FDA guidance for CDI-45205 support upcoming clinical study plans.
Cocrystal Pharma (Nasdaq: COCP) announced receiving FDA guidance for the development of CDI-45205, a novel SARS-CoV-2 protease inhibitor, as a potential COVID-19 treatment. The FDA's response, which followed a pre-IND briefing, provides insights necessary for advancing the clinical development, including plans for a Phase 1 study set to begin in 2022. Cocrystal aims to conduct formulation development and IND-enabling studies, emphasizing the compound's antiviral efficacy against various SARS-CoV-2 variants, including Omicron.
Cocrystal Pharma (Nasdaq: COCP) announced its participation in the H.C. Wainwright BioConnect Virtual Conference from January 10-13, 2022. A webcast of the presentation will be available on January 10, 2022, at 7:00 a.m. ET. The company aims to initiate first-in-human studies for two SARS-CoV-2 antivirals targeting COVID-19 and is progressing with its influenza A Phase 1 trial. Cocrystal is well positioned financially with a solid cash position and a debt-free balance sheet, allowing it to advance its clinical plans.
Cocrystal Pharma (Nasdaq: COCP) announced significant progress in combating COVID-19, confirming its protease inhibitors' efficacy against the Omicron variant and other strains. The company plans to initiate Phase 1 clinical studies for its intranasal and oral COVID-19 protease inhibitors, CDI-45205 and another yet-to-be-named oral inhibitor, shortly. Their inhibitors have exhibited broad-spectrum activity and promising safety profiles in preclinical studies, displaying no cytotoxicity and good bioavailability.
Cocrystal Pharma, Inc. (Nasdaq: COCP) announced that President and interim CEO Sam Lee and CFO James Martin will present a company overview during the Noble Capital Markets Virtual Roadshow on December 8, 2021. The presentation will discuss Cocrystal's progress towards initiating clinical studies in 2022 for two COVID-19 protease inhibitors, which have shown broad-spectrum activity against variants including Delta. The company awaits FDA feedback on its IND briefing for its intranasal COVID-19 inhibitor and plans to submit another for its oral inhibitor in early 2022.
Cocrystal Pharma (Nasdaq: COCP) unveiled its clinical plans for two antiviral compounds targeting COVID-19 at the World Antiviral Congress 2021. The company presented promising preclinical data on CDI-45205, an intranasal lead, and oral protease inhibitors. The Phase 1 and Phase 2 trials are expected to assess safety and efficacy, focusing on the treatment of mild to moderate COVID-19. Cocrystal's inhibitors demonstrated broad-spectrum antiviral activity against multiple SARS-CoV-2 variants. The company is awaiting FDA feedback on its pre-IND briefing package.